

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-19 (Cancelled).

20. (Currently amended) An isolated polypeptide comprising the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.

21. (Currently amended) The polypeptide of Claim 20 comprising the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that added.

22. (Currently amended) The polypeptide of Claim 20 comprising the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are deleted.

23. (Currently amended) The polypeptide of Claim 20 comprising the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are conservatively substituted.

24. (Currently amended) The polypeptide of Claim 20 comprising the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6).

25. (Currently amended) An isolated polypeptide comprising an extracellular ~~region~~ segment of the ~~PF4AR~~-amino acid sequence of Figure 5 (SEQ ID NO:6).

26. (Cancelled).

27. (Currently amended) The polypeptide of Claim 25, wherein the extracellular ~~region~~ segment comprises the N-terminal fragment.

28. (Cancelled).

29. (Previously presented) A composition comprising the polypeptide of Claim 20 and a pharmaceutically acceptable carrier.

30. (Previously presented) A composition comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

31 - 73 (Cancelled).